300725SZSE

2026 Semi-Annual Report Summary

PharmaBlock Sciences (Nanjing) , Inc.··3 pages

✨ AI Summary

PharmaBlock Sciences (Nanjing) Co., Ltd. reported a 15.19% increase in revenue to 1.06 billion RMB and a 37.17% rise in net profit attributable to shareholders to 99.44 million RMB for the first half of 2026. The board approved a profit distribution plan of 1 RMB per 10 shares. The company confirmed no changes in control or material adverse events during the reporting period.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

I. Important Notes

This semi-annual report summary is derived from the full semi-annual report. Investors should read the full report on the media designated by the China Securities Regulatory Commission to fully understand the company's operating results, financial position, and future development plans. All directors attended the board meeting to review this report.

Profit distribution plan or capital reserve conversion plan for the reporting period: Applicable.

The company's profit distribution plan approved by the board is: Based on 232,971,251 shares, a cash dividend of 1 RMB (tax included) will be distributed for every 10 shares to all shareholders. No bonus shares will be issued, and no capital reserve will be converted into share capital.

II. Company Profile

1. Company Introduction

ItemDetails
Stock AbbreviationPharmaBlock
Stock Code300725
Stock ExchangeShenzhen Stock Exchange

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.